ANTIVIRAL COMPOSITION FOR SARS-COV-2 AND HCOV-OC43 COMPRISING RHEIN, MECLOFENAMIC ACID, OR A COMBINATION THEREOF
The present invention relates to an antiviral composition for Betacoronavirus comprising rhein and meclofenamic acid as active components. When the antiviral composition of the present invention is used, an antiviral effect is demonstrated whereby the viral RNA level of SARS-CoV-2 and HCoV-OC43 is suppressed, and thus it is possible to treat or prevent COVID-19 or a cold.
1 .- 7 . (canceled)
8 . A method for treating a disease caused by viral infection of Betacoronavirus, comprising:
administering to a subject in need thereof a composition comprising as an active ingredient rhein, meclofenamic acid, or a combination thereof.
9 . The method of claim 8 , wherein the Betacoronavirus includes human coronavirus OC43 (HCoV-OC43), human coronavirus HKU1 (HCoV-HKU1), severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).
10 . The method of claim 8 , wherein the active ingredient inhibits the viral RNA level of at least one selected from the group consisting of non-structural protein (Nsp), spike (S), envelope (E), membrane (M), nucleocapsid (N), and hemagglutinin esterase (HE) protein of the Betacoronavirus.
11 . The method of claim 10 , wherein the non-structural protein (Nsp) is at least one protein selected from the group consisting of Nsp1, Nsp2, Nsp3, Nsp4, Nsp5, Nsp6, Nsp7, Nsp8, Nsp9, Nsp10, Nsp11, Nsp12, Nsp13, Nsp14, Nsp15, and Nsp16.
12 . The method of claim 8 , wherein the antiviral composition further comprises a pharmaceutically acceptable carrier, vehicle, excipient, stabilizer, or diluent.
13 . A method for preventing or treating coronavirus disease 2019 (COVID-19), comprising:
administering to a subject in need thereof a composition comprising as an active ingredient rhein, meclofenamic acid, or a combination thereof.
14 . A method for preventing or treating common cold, acute upper respiratory tract infection, severe acute respiratory syndrome, or viral pneumonia, comprising:
administering to a subject in need thereof a composition comprising as an active ingredient rhein, meclofenamic acid, or a combination thereof.